Table 1. Patients' characteristics, original cohort.
| Characteristics | Total | Group I, No. (%) | Group II, No. (%) | p-value | |
|---|---|---|---|---|---|
| No. of patients | 166 | 112 | 54 | ||
| Age (median/mean/standard deviation) | 55/53.8/9.6 | 56.5/55.5/12.3 | 0.350 | ||
| FIGO substage (1988) | |||||
| IIB | 8 | 8 (7.1) | 0 | 0.163 | |
| IIC | 70 | 45 (40.2) | 25 (46.3) | ||
| IIIA | 14 | 8 (7.1) | 6 (11.1) | ||
| IIIB | 9 | 5 (4.5) | 4 (7.4) | ||
| IIIC (T3N0) | 31 | 29 (25.9) | 2 (3.7) | ||
| IIIC (TXN1) | 21 | 10 (8.9) | 11 (20.4) | ||
| IV | 13 | 7 (6.3) | 6 (11.1) | ||
| Initial surgery | <0.001 | ||||
| TH+BSO+OM+SRL | 112 | 112 (100.0) | 0 | ||
| TH+BSO±OM | 41 | 0 | 41 (75.9) | ||
| TH+USO±OM | 3 | 0 | 3 (5.6) | ||
| BSO±OM | 2 | 0 | 2 (3.7) | ||
| USO±OM+RPN | 1 | 0 | 1 (1.9) | ||
| USO±OM | 4 | 0 | 4 (7.4) | ||
| Tumorectomy±OM | 3 | 0 | 3 (5.6) | ||
| Ascites volume (mL) | 0.682 | ||||
| <100 | 126 | 84 (75.0) | 42 (77.8) | ||
| 100–499 | 22 | 17 (15.2) | 5 (9.3) | ||
| 500–1,000 | 6 | 4 (3.6) | 2 (3.7) | ||
| >1,000 | 12 | 7 (6.3) | 5 (9.3) | ||
| Preoperative CA125 value (U/mL) | 0.363 | ||||
| ≤35 | 36 | 22 (19.6) | 14 (25.9) | ||
| >35 | 130 | 90 (80.4) | 40 (74.1) | ||
| Chemotherapy | 0.589 | ||||
| None | 6 | 3 (2.7) | 3 (5.6) | ||
| TP | 122 | 82 (73.2) | 40 (74.1) | ||
| Non-TP | 38 | 27 (24.1) | 11 (20.4) | ||
Group I is patients with full-staging standard surgery and group II is patients with non-staging limited surgery.
BSO, bilateral salpingo-oophorectomy; CA125, cancer antigen 125; FIGO, Internatinal Federation of Gynecology and Obstetrics; NA, not applicable; OM, omentectomy; RPN, retroperitoneal lymphadenectomy; SRL, systematic retroperitoneal lymphadenectomy; TH, total hysterectomy; TP, taxane plus platinum; USO, unilaretal salpingo-oophorectomy.